Skip to main content
    I

    Integra LifeSciences Holdings (IART)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $13.98
    -0.42 (-2.92%)

    Market Cap: $1.12B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Integra LifeSciences Holdings (IART) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Integra LifeSciences Holdings (IART) trades at 5.5x trailing earnings and 0.7x sales. Its P/E of 5.5x is below its 5-year median of 10.5x. Its forward P/E is 5.9x. The median P/E across 6 similar companies is 34.6x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 6.8% lower over the next year. Its free cash flow yield is 7.9%.

    MultipleValue
    P/E (trailing)5.5x
    Forward P/E5.9x
    Price to sales0.7x
    Price to book1.0x
    EV/EBITDA11.1x
    Price to FCF12.6x
    EV/FCF32.8x
    PEG0.7
    FCF yield7.9%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 71.8% below 19.5x, its P/S is 76.7% below 3.0x and its P/B is 66.7% below 3.0x.

    MultipleCurrent5-year median10-year median
    P/E5.5x10.5x19.5x
    P/S0.7x1.6x3.0x
    P/B1.0x1.5x3.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 116 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 5.6x in 2025 to 26.5x in 2020. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$12.425.6x0.6x0.9x
    2024$22.688.9x1.1x1.1x
    2023$43.5514.0x2.3x2.1x
    2022$56.0716.7x3.0x2.6x
    2021$66.9921.1x3.7x3.4x
    2020$64.9226.5x4.0x3.6x
    2019$58.2821.3x3.3x3.6x
    2018$45.1018.6x2.5x2.8x
    2017$47.8624.8x3.1x4.0x
    2016$42.9024.4xN/A4.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IART

    What is IART's forward P/E ratio?

    Integra LifeSciences Holdings has a forward P/E ratio of 5.9x.

    Is IART stock overvalued?

    GNG's valuation label for IART is Undervalued. Its P/E of 5.5x compares with a median of 34.6x across 6 similar companies.

    What is IART's price to sales ratio?

    Integra LifeSciences Holdings has a price to sales ratio of 0.7x.

    What is Integra LifeSciences Holdings's average P/E ratio over 5 years?

    Integra LifeSciences Holdings's median P/E over the last 5 years is 10.5x, from 60 month-end values through Oct 2026.

    What is IART's PEG ratio?

    Integra LifeSciences Holdings has a PEG ratio of 0.7.